Although several preclinical studies suggest that aberrations in the PI3K/AKT/mTOR and the MAP kinase pathway may co-exist, only limited studies in patients have been undertaken, and have mostly concentrated on colorectal cancer.[8], [10], [11] We, therefore, investigated the PIK3CA, RAS (KRAS and NRAS) and BRAF mutation status of a large group of patients (N = 504) with advanced cancers referred to the Clinical Center for Targeted Therapy (CCTT) at The University of Texas MD Anderson Cancer Center (MD Anderson). The gene discussed is PIK3CA; the disease is cancer.